Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinic

1 Oct 2013

Abstract excerpt

Genetic testing may help to improve treatment outcomes in order to avoid non-response or severe side effects to psychotropic medication. Most robust data have been obtained for gene variants in CYP2D6 and CYP2C19 enzymes for antipsychotics and antidepressant treatment. We reviewed original articles indexed in PubMed from 2008-2013 on CYP2D6 and CYP2C19 gene variants and treatment outcome to antidepressant or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Schizophrenia research and treatment
Share to Treatment of Major Depression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24151801
DOI: 10.3109/09540261.2013.838944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicPMID 24151801Read ↗

Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.Semantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

CYP2C19 genotype-phenotype correlation: current insights and unanswered questionsSemantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring dataSemantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.Semantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.